Lead Product(s): EI-1071
Therapeutic Area: Neurology Product Name: EI-1071
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Pangu Capital
Deal Size: $27.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing August 23, 2021
Proceeds will be used to advance phase 1 trials of two pipeline candidates, EI-1071 and EI-001 and take three immuno-oncology assets towards IND applications .